Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
PDL BIOPHARMA, INC. v. MERCK SHARP & DOHME CORP.
Case Number:
1:16-cv-00407
Court:
Nature of Suit:
Judge:
Firms
Companies
Sectors & Industries:
-
April 25, 2017
Merck Settles Keytruda Patent Suit For $19.5M
Merck Sharp & Dohme Corp. and PDL BioPharma Inc. have called a truce in a patent infringement dispute over Merck's cancer drug Keytruda, as the companies announced Monday that Merck will pay $19.5 million to license related patent rights and dismiss the case.
-
January 26, 2016
Merck Hit With Patent Suit Over Cancer Drug Keytruda
PDL BioPharma Inc. blasted Merck Sharp & Dohme Corp. over cancer drug Keytruda in New Jersey federal court Monday, alleging the medication infringes on the company's patent related to a type of antibody used in treatments that attack cancer cells without damaging healthy cells.